



5th Annual BREAST CANCER SYMPOSIUM

Disparities on a Cellular Level & Patient Level

A CME-accredited, 3-day educational conference

August 4-6, 2023

Live In-Person @ The Hudson Hall,
Hudson, NY

This activity has been approved for

19.5 AMA PRA
Category 1 Credits™

COMMUNITY-BASED
CANCER CARE AFFILIATE



ACCREDITED BY:



ORGANIZED BY:



CONFERENCE
COLLABORATOR:



Dear Breast Cancer Symposium Attendees:

It is my pleasure to welcome you to New York Oncology Hematology's 3rd Annual Breast Cancer Symposium. We are so excited by the tremendous growth and prominence of this event. Of course we also look forward to the time when we can come together in person and celebrate the remarkable advances in breast cancer care. Those days are right around the corner!

This conference expresses the passion and compassion of our conference Course Chair and Moderator, Dr. Maria Theodoulou, for the holistic care of women with breast cancer. Ever grounded in science, with rapidly evolving data of translational research trials, and delivered by an esteemed faculty in the breast cancer world.

We thank our event sponsors for their support to bring this conference to you.

Thank you so much for attending and enjoy this engaging time together!

Sincerely,

A handwritten signature in black ink, appearing to read 'Todd Doyle', with a stylized flourish at the end.

Todd Doyle, MD
President, New York Oncology Hematology

Dear Friends and Colleagues,

This year on August 4th to August 6th, 2023, New York Oncology Hematology is proud to present the Fifth Annual Breast Cancer Symposium, “Disparities on a Cellular Level and Patient Level.” This is a particularly relevant theme as the oncology community, as well as the patients that we care for, are struggling to understand the variations of breast cancer presentations, the disparities within patient populations and prognosis, and the multiple subsets of molecular interrogations that lead us to patient-directed targeted and individualized therapy.

I want to thank everyone on behalf of New York Oncology Hematology for supporting the 5th Annual Breast Cancer Symposium, a CME educational program, held at Hudson Hall, Hudson, New York. I am grateful to the nationally and internationally recognized faculty presenting the results of cutting-edge research that guides our treatment of patients with breast cancer on a daily basis. I am grateful to the attendees who want to take this information back to their clinical practices, confirming the excellence of care that they are already performing, or adding to that excellence of care. I am grateful for all the grant support received for this symposium which has allowed us to offer this program free of charge.

This year our program is live, which allows us to come together in an auditorium setting, interacting, sharing information, and building on the hope of tomorrow and for future educational symposiums.

Thank you for being part of this educational event. We are all excited on the podium side, and I hope you are all excited as attendees.

Most importantly, I want to thank our patients for trusting us to bring them the newest standards of care for treatment and support. Patients allow us access into their intimate private world, motivating us to be our best. The least that we can do is understand not only the differences in our patient populations but the differences and disparities in their presenting cancers, the natural history of the individual breast cancer diagnosis, as well as the socioeconomic environment and hereditary vulnerability that may influence the patient’s prognosis and importantly guide therapeutic recommendations.

Sincerely,

A handwritten signature in black ink, reading "Maria Theodoulou". The signature is fluid and cursive, with the first name "Maria" and last name "Theodoulou" clearly distinguishable.

Maria Theodoulou, MD
Program Chair
Program Director
Breast Cancer Medicine
New York Oncology Hematology

CONFERENCE AGENDA

General Sessions: PERFORMANCE HALL – 2nd Floor

Exhibits and Food: CENTER HALL AND COMMON COUNCIL – 1st Floor

Product Theaters: WEST ROOM / VAULT – 1st Floor

DAY 1 - FRIDAY, AUGUST 4, 2023

7:30 AM – 8:50 AM	Registration, Exhibits, Optional Ancillary Events	
7:50 AM – 8:50 AM	Optional Non-CME Ancillary Event <i>Clinical Case Reviews: Treatment of a Broad Range of Patients With HR+/HER2- Metastatic Breast Cancer</i> Presenter: Dr. Neil Iyengar Supporter: Pfizer	WEST ROOM / VAULT
8:55 AM – 9:05 AM	Introduction / Opening	Dr. Maria Theodoulou (NYOH), Dr. Todd Doyle (NYOH)
9:05 AM – 9:25 AM	OPENING CONFERENCE PRESENTATION	Dr. Frank Arena (NYU)
9:25 AM – 9:55 AM	Breast Imaging	Dr. Elizabeth Morris (UC Davis)
9:55 AM – 10:35 AM	Overdiagnosis and Active Surveillance of DCIS	Dr. Jennifer Marti (Mt Sinai)
10:35 AM – 11:15 AM	Breast Surgery: Updates Post Neoadjuvant Therapy	Dr. Eleftherios Mamounas (UF)
11:15 AM – 11:45 AM	Breast Reconstruction: Challenges Post Neoadjuvant Chemotherapy and Radiation	Dr. Babak Mehrara (MSKCC)
11:45 AM – 12:45 PM	Break, Exhibits, Optional Ancillary Events	
11:45 AM – 12:45 PM	Optional Non-CME Ancillary Event <i>Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings.</i> PP-AL-US-2989 © Lilly USA, LLC 2021. All rights reserved. Presenter: Dr. Peter Kaufman Supporter: Eli Lilly and Company	WEST ROOM / VAULT
12:45 PM – 1:15 PM	Obesity, Estrogen, and Breast Cancer	Dr. Neil Iyengar (MSKCC)
1:15 PM – 1:45 PM	Optimizing Self, Health and Nutrition	Dr. Neil Iyengar (MSKCC)
1:45 PM – 2:15 PM	Triple Negative Breast Cancer / Early	Dr. Tiffany Traina (MSKCC)
2:15 PM – 2:45 PM	Triple Negative Breast Cancer / Late	Dr. Tiffany Traina (MSKCC)
2:45 PM – 2:55 PM	Break	
2:55 PM – 3:25 PM	Disparities Genetics and Breast Cancer	Dr. Mark Robson (MSKCC)
3:25 PM – 3:55 PM	Updates on Radiation Therapy - Are there disparities?	Dr. Yasmin Hasan (UOC)
3:55 PM – 4:25 PM	Radiation Therapy: Who doesn't need it?	Dr. Quincey LaPlant (MSKCC)
4:25 PM – 5:15 PM	Community Case Presentations	Dr. Frank Arena (NYU), Dr. Hyman Muss (UNC), Dr. Beryl McCormick (MSKCC), Dr. Maria Theodoulou (NYOH)
5:15 PM – 5:15 PM	Closing Remarks	Dr. Maria Theodoulou (NYOH)
5:15 PM – 5:35 PM	SPECIAL PERFORMANCE	Singer/Songwriter Donna Lewis
5:30 PM – 6:15 PM	Optional Non-CME Ancillary Event <i>Addressing the Needs of Patients Across the HR+/HER2- Landscape</i> Presenter: Patrick Kugel Supporter: Novartis Oncology	WEST ROOM / VAULT
5:30 PM – 7:00 PM	Meet and Greet Networking – This is an opportunity to unwind and network – featuring local Wines, Brews, Spirits and Charcuterie inspired food.	ALL

DAY 2 - SATURDAY, AUGUST 5, 2023

7:30 AM – 8:55 AM	Registration, Exhibits, Optional Ancillary Events	
7:50 AM – 8:50 AM	Optional Non-CME Ancillary Event <i>Brain Metastases in HER2+ Metastatic Breast Cancer: Current Clinical Insights</i> Presenter: Dr. Joyce O'Shaughnessy Supporter: Seagen	WEST ROOM / VAULT
8:55 AM – 9:35 AM	SPECIAL LECTURE: PRECISION MEDICINE: THE NEW PATHOLOGY	Dr. George Sledge (CLS)

9:35 AM – 10:05 AM	Break	
10:05 AM – 11:05 AM	Antibody Drug Conjugates	Dr. Komal Jhaveri (MSKCC)
11:05 AM – 12:05 PM	KEYNOTE: Is Monitoring for Minimal Residual Disease in Breast Cancer of Clinical Utility?	Dr. Joyce O'Shaughnessy (TO-BCC)
12:05 PM – 1:05 PM	Break, Exhibits, Optional Ancillary Events	
12:05 PM – 1:05 PM	Optional Non-CME Ancillary Event <i>Expanded Horizons: A Post-endocrine Option for Patients with HR+/HER2-mBC</i> Presenter: Dr. Anne O'Dea Supporter: Gilead Sciences, Inc.	WEST ROOM / VAULT
1:05 PM – 1:35 PM	Updates in Hormone Receptor Positive Breast Cancer - Adjuvant and Neoadjuvant	Dr. Claudine Isaacs (GU)
1:35 PM – 2:05 PM	Updates in Hormone Receptor Positive Breast Cancer - Metastatic	Dr. Claudine Isaacs (GU)
2:05 PM – 3:05 PM	Immunotherapy	Dr. VK Gadi (UIC)
3:05 PM – 3:35 PM	Moral Injury and Physicians: Burned or Burnout?	Dr. Anne O'Dea (KUMC)
3:35 PM – 4:05 PM	Ethical Dilemmas & Disparities in Patient Care	Dr. Frank Arena (NYU)
4:05 PM – 4:10 PM	Closing Remarks	Dr. Maria Theodoulou (NYOH)
4:10 PM – 5:10 PM	Optional Non-CME Ancillary Event <i>Educational presentation detailing the once-daily oral ORSERDU (elacestrant) medication.</i> Presenter: Dr. VK Gadi Supporter: Stemline Therapeutics	WEST ROOM / VAULT
5:10 PM – 6:00 PM	Meet and Greet Networking – This is an opportunity to unwind and network – featuring local Wines, Brews, Spirits and Charcuterie inspired food.	ALL

DAY 3 - SUNDAY, AUGUST 6, 2023

7:30 AM – 8:45 AM	Registration, Exhibits, Optional Ancillary Events	
8:50 AM – 8:55 AM	INTRODUCTION/HIGHLIGHTS FROM SATURDAY	Dr. Maria Theodoulou (NYOH)
8:55 AM – 9:25 AM	Disparities in Real World Medicine	Dr. Anne O'Dea (KUMC)
9:25 AM – 9:30 AM	Arena Advocacy Awardee - 2023 Recipient	Dr. Maria Theodoulou (NYOH), Dr. Frank Arena (NYU)
9:30 AM – 10:00 AM	The Disparities in Treating the Older Patient	Dr. Hyman Muss (UNC)
10:00 AM – 10:10 AM	Break	
10:10 AM – 10:40 AM	HER2neu + Breast Cancer / Early	Dr. Chau Dang (MSKCC)
10:40 AM – 11:10 AM	HER2neu + Breast Cancer / Late	Dr. Chau Dang (MSKCC)
11:10 AM – 11:40 AM	HER2neu and the Older Patient	Dr. Hyman Muss (UNC)
11:40 AM – 12:40 PM	Break, Exhibits, Optional Ancillary Events	
11:40 AM – 12:40 PM	Optional Non-CME Ancillary Event <i>An Overview of Clinical Data for ENHERTU (fam-trastuzumab deruxtecan-nxki) in HER2-Expressing Metastatic Breast Cancer</i> Presenter: Dr. Frances Arena Supporter: Daiichi Sankyo Inc. and AstraZeneca	WEST ROOM / VAULT
12:40 PM – 1:40 PM	Breast Cancer and the Brain	Dr. Jessica Wilcox (MSKCC)
1:40 PM – 2:10 PM	SPECIAL LECTURE: The Legal Health of the Medical Professional	Will Newman (Oberheiden, P.C.)
2:10 PM – 2:40 PM	SPECIAL LECTURE: Sexual Rehabilitation After Cancer: The Physical and Emotional Issues	Dr. Jeanne Carter (MSKCC)
2:40 PM – 3:40 PM	HER2 Anything: What are we doing Monday morning that we did not do a year ago, and what we might be doing a year from now.	Dr. Edith Perez (MAYO)
3:40 PM – 4:10 PM	HPV in the Adult Woman	Dr. Heidi Godoy (NYOH)
4:10 PM – 4:55 PM	Community Case Discussions	Dr. Frank Arena (NYU), Dr. Chau Dang (MSKCC), Dr. Hyman Muss (UNC), Dr. Maria Theodoulou (NYOH), Dr. Jessica Wilcox (MSKCC)
4:55 PM – 5:00 PM	SUNDAY SESSION CLOSE	Dr. Maria Theodoulou (NYOH)

PROGRAM OVERVIEW

As breast cancer is a multi-faceted disease, the 5th Annual Breast Cancer Symposium aims to update practitioners on the rapidly evolving evidence-based data for diagnosing and treating breast cancer.

The 5th Annual Breast Cancer Symposium: Disparities on a Cellular Level & Patient Level is being organized in collaboration with the Medical Society of the State of New York, the American Cancer Society, Susan G Komen and myMedEd, Inc. This accredited conference will offer 19.5 continuing education credits and is scheduled for August 4-6, 2023. The conference will be live in person at Hudson Hall in Hudson, NY. The conference will be recorded and offered online for free for on-demand viewing within 90 days after the conference.

EDUCATIONAL GOAL

Progress in our understanding of breast cancer's genetic and physiologic pathways has led to the development of targeted systemic therapies, improved surgical procedures and radiation techniques, and improved disease-free and overall survival benefits. This conference aims to educate the medical and global community in a forum that will facilitate the utilization of optimal treatment strategies and foster communication that will benefit the individual patient and the community.

TARGET AUDIENCE

This activity has been designed for medical, surgical, and radiation oncologists, primary care physicians, gynecologists, medical professionals and health care professionals interested in expanding their knowledge for the diagnosis, treatment, and management of the breast cancer patient.

HOW TO CLAIM CREDIT

- SIGN IN EACH DAY OF THE CONFERENCE.
- YOU WILL BE EMAILED INSTRUCTIONS FOR COMPLETING A PROGRAM EVALUATION, CLAIMING YOUR CERTIFICATE OF CREDITS, AND PRINTING YOUR CERTIFICATE WITHIN 7 DAYS AFTER THE CONFERENCE.

CONFERENCE RECORDINGS

Within 90 days, the conference recordings will be available for viewing. An email will be sent when the recording is available. The recording is not going to be accredited for continuing education credits.

LEARNING OBJECTIVES

After completing this activity, participants will be able to:

- Review the recent developments in breast surgical approaches, including upfront and after neoadjuvant chemotherapy, including the decision-making approach to axillary interrogation.
- Discuss the disparities encountered and identified in the breast cancer patient.
- Explain the rationale for reconstruction options post neoadjuvant chemotherapy and radiation therapy.
- Discuss updates in breast cancer imaging for earlier detection.
- Explore the understanding of subsets of aggressive breast pathology and molecular profiling.
- Identify therapeutic advances in early and advanced hormone receptor-positive, HER2 neu overexpressing, and triple-negative breast cancer.
- Review the advances in radiation therapy and outcomes, including short-course radiation therapy and de-escalation, and who may not need radiation therapy in breast conservation.
- Describe the management of HER2-positive early breast cancer in the older patient and
- Understand the psychosocial, histologic and treatment disparities of the older breast cancer patient.
- Understanding genetic mutations and approach to treatment.
- Identify the new and emerging systemic treatment options for breast cancer brain metastases beyond surgery and radiotherapy.
- Understanding the science and therapeutic options using molecular profiling for patients with breast cancer.
- Explain the mechanism of action and rationale for immunotherapy.
- Discussing the psychosocial health of the oncology health provider.
- Updates on nutritional health for patients with early and advanced breast cancer.
- Bone health and when and when not to intervene

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and myMedEd, Inc. MSSNY is accredited by the ACCME to provide continuing medical education for physicians.



CREDIT DESIGNATION STATEMENT

The Medical Society of the State of New York designates this live activity for a maximum of 19.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME, please consult your professional licensing board.

As an ACCME-accredited provider, MSSNY will identify and mitigate relevant financial relationships of all individuals who control CME content.

ASSURANCE OF BALANCED, UNBIASED, AND FAIR CONTENT

As an ACCME-accredited provider, MSSNY must identify and mitigate relevant financial relationships of all individuals controlling CME content.

Financial relationships are relevant if the following three conditions are met for the prospective person who will control the content of the education:

- A financial relationship, in any amount, exists between the person in control of content and an ineligible company.
- The financial relationship existed during the past 24 months.
- The educational content is related to the products of an ineligible company with whom the person has a financial relationship.

Mechanisms to ensure that presentations are free from commercial bias are in place. Faculty will also disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.

PLANNER DISCLOSURES

Nicole Falco: Nothing to disclose.

Susan Urban: Nothing to disclose..

FACULTY DISCLOSURES

NAME	ROLE	COMPANY NAME	REL.
Anne O'Dea, MD	Faculty	AstraZeneca	C
	Faculty	Daiichi Sankyo	C
	Faculty	Gilead	C
	Faculty	Lilly	C
	Faculty	Novartis	C
	Faculty	Pfizer	C
	Faculty	Puma	C
	Faculty	Seagen	C
	Faculty	Stemline	C
	Faculty	Elsevier	RP
Babak Mehrara, MD	Faculty	Integra Corp	I
	Faculty	Medflox Corp	C
	Faculty	Pfizer	I
	Faculty	PureTech Corp	I, RP
Beryl McCormick, MD	Faculty	Regeneron Corp	I
	Faculty	None	N/A
Chau Dang MD	Faculty	AstraZeneca	C, AB, S, RSI
	Faculty	Genentech	C, AB, S, RSI
	Faculty	Gilead	C, AB, S, RSI
	Faculty	Novartis	C, AB, S, RSI
	Faculty	Pfizer	C, A, S
	Faculty	Puma	RSI
	Faculty	Roche	C, AB, S, RSI
	Faculty	Seagen	C, AB, S, RSI
	Faculty	AstraZeneca	C
	Faculty	AstraZeneca	RSI
Claudine Isaacs, MD	Faculty	Biotheranostics	C
	Faculty	BMS	RSI
	Faculty	Genentech	C, RSI
	Faculty	Gilead	C
	Faculty	GSK	RSI
	Faculty	McGraw Hill	RP
	Faculty	Novartis	C, RSI
	Faculty	Pfizer	C, RSI
	Faculty	Puma	C
	Faculty	Seagen	RSI
Edith Perez, MD	Faculty	Wolters Kluwer	RP
	Faculty	None	N/A
	Faculty	Biotheranostics	C
	Faculty	Exact Sciences	C, S
	Faculty	Genentech	C, S
	Faculty	Merck	C, S
	Faculty	Sanofi Genzyme	C
	Faculty	TerSera Therapeutics	C
	Faculty	Bayer	C
	Faculty	Guerbet	C
Elizabeth Morris, MD	Faculty	Kheiron Medical	AB
	Faculty	AstraZeneca	C
	Faculty	Coherus	C
	Faculty	Daiichi Sankyo	C
	Faculty	Incyte	C
	Faculty	Merck	C
	Faculty	Optimus Health	C
	Faculty	Puma	C
	Faculty	Regeneron	C
	Faculty	Stemline	C
Heidi Godoy, MD	Faculty	Eisai	S
	Faculty	GSK	S
	Faculty	Immunogen	S
	Faculty	Seagen	S
Hyman Muss, MD	Faculty	None	N/A
	Faculty	Sprout	AB, RSI
Jeanne Carter, MD	Faculty	None	N/A
	Faculty	Apellis Pharmaceutical	C
Joyce O'Shaughnessy, MD	Faculty	Aptitude Health	C, AB
	Faculty	AstraZeneca	C, AB
	Faculty	Daiichi Sankyo	C, AB
	Faculty	Eisai	C, AB
	Faculty	Loxo Oncology	C, AB
	Faculty	Merck	C, AB
	Faculty	Novartis	C, AB
	Faculty	Pierre Fabre	C, AB
	Faculty	Puma	C, AB
	Faculty	Roche	C, AB
Komal Jhaveri, MD	Faculty	Sanofi	C, AB
	Faculty	Seagen	C, AB
	Faculty	Stemline	C, AB
	Faculty	AstraZeneca	C, RSI

	Faculty	Blueprint Medicine	C
	Faculty	Daiichi Sankyo	C
	Faculty	Genentech/Roche	C, RSI
	Faculty	Gilead	C, RSI
	Faculty	Lilly/Loxo Oncology	C, RSI
	Faculty	Merck	RSI
	Faculty	Novartis	C, RSI
	Faculty	Olema Pharmaceuticals	C
	Faculty	Scorpion Therapeutics	C, RSI
	Faculty	Seagen	C
Maria Theodoulou, MD	Faculty	Stemline/Menarini	C
	Faculty	Zymeworks	C, RSI
	Course Chair / Faculty	Daiichi Sankyo/AstraZeneca	S
	Course Chair / Faculty	Seagen	S
Mark Robson, MD	Course Chair / Faculty	Stemline	S
	Faculty	Artios Pharma	CU, RSI
	Faculty	AstraZeneca	CU, RSI, ES
	Faculty	Bristol Myers-Squibb	CU
	Faculty	Change Healthcare	C
	Faculty	GSK	CU
	Faculty	Merck	CU, RSI
	Faculty	Pfizer	CU, ES
	Faculty	Tempus Labs	CU
	Faculty	Zenith Pharma	CU
Neil Iyengar, MD	Faculty	AstraZeneca	C
	Faculty	BD Life Sciences	C
	Faculty	Gilead	C
	Faculty	Novartis	C
	Faculty	Pfizer	C
	Faculty	Puma	C
	Faculty	Seagen	C
	Faculty	TerSera Therapeutics	C
	Conference Organizer	None	N/A
	Faculty	None	N/A
Quincey LaPlant, MD	Faculty	None	N/A
	Faculty	None	N/A
Susan Urban	MSSNY CME Monitor	None	N/A
	Faculty	Astellas Pharma	RSI
Tiffany Traina, MD	Faculty	AstraZeneca	C, RSI
	Faculty	Ayala Pharmaceuticals	RSI
	Faculty	Biotheranostics	C
	Faculty	Daiichi Sankyo	C, RSI
	Faculty	Exact Sciences	C
	Faculty	G1 Therapeutics	C
	Faculty	GE Healthcare	C
	Faculty	Genentech/Roche	C, RSI
	Faculty	Gilead Sciences	C
	Faculty	GSK	C
Vijayakrishna Gadi, MD	Faculty	Hengrui Pharmaceutical	C
	Faculty	Merck	C
	Faculty	Novartis	C
	Faculty	Pfizer	C, RSI
	Faculty	Stemline	C
	Faculty	TerSera Therapeutics	C
	Faculty	3rdEyeBio	F
	Faculty	Agenda	RSI
	Faculty	AmunBio	C
	Faculty	Emerging Markets Cancer Ignition Fund	BM
	Faculty	Gilead	C
	Faculty	Hologics	C, S
	Faculty	New Equilibrium Biosciences	BM
	Faculty	Novartis	RSI
	Faculty	Phoenix Molecular Designs	BM
	Faculty	Puma	S, BM
	Faculty	Roche	S
	Faculty	Seagen	C, S
	Faculty	Sengine Precision Medicine	F
	Faculty	Stemline	S
Will Newman	Faculty	Tizona Therapeutics	RSI
	Faculty	None	N/A
Yasmin Hasan, MD	Faculty	None	N/A

S = Speaker, C = Consultant, CU = Consultant Uncompensated, RSI = Research Support Paid to Institution, F = Founder, BM = Board Member, AB = Advisory Board, I = Investigator, RP = Royalty Payment

All relevant financial relationships have been mitigated.

FACULTY



Maria Theodoulou, MD
(Course Chair & Moderator)

Program Director
Breast Cancer Medicine
New York Oncology Hematology
Albany, NY



Francis Arena, MD

Director NYU Langone Arena
Oncology
Clinical Professor NYU Health
Medical College
President and Director of
Research Sass Foundation for
Medical Research
Lake Success, NY



Jeanne Carter, PhD

Head of the Family Sexual
Medicine Program/Attending
Psychologist
Memorial Sloan Kettering Cancer
Center
New York, NY



Chau T. Dang, MD

Medical Director MSK
Westchester Medical Oncology
Attending, Breast Medicine
Service
Memorial Sloan Kettering Cancer
Center
New York, NY



VK Gadi, MD, PhD

Deputy Director
University of Illinois Cancer
Center
Director, Medical Oncology
University of Illinois Chicago
Chicago, IL



Heidi Godoy, DO


Gynecologic Oncologist
New York Oncology Hematology
Albany, NY



Yasmin Hasan, MD


Associate Professor
Department of Radiation and
Cellular Biology
Residency Program Director
Director, Gynecological
Brachytherapy
University of Chicago Medical
Center
Chicago, IL

FACULTY



**Claudine Isaacs, MD,
FRCP**

Professor of Medicine and
Oncology
Associate Director Clinical
Research Leader, Clinical Breast
Cancer Program
Lombardi Comprehensive Cancer
Center
Georgetown University
Washington, DC



Neil Iyengar, MD

Associate Attending Physician
Memorial Sloan Kettering Cancer
Center
Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending
Rockefeller University
New York, NY



Komal Jhaveri, MD, FACP

Associate Attending Physician
Section Head, Endocrine Therapy
Research Program
Clinical Director, Early Drug
Development Service
Memorial Sloan Kettering Cancer
Center
New York, NY



**Quincey LaPlant, MD,
PhD**

Assistant Attending Radiologist
Oncologist
Memorial Sloan Kettering Cancer
Center
New York, NY



**Terry P. Mamounas, MD,
MPH, FACS**

Medical Director Comprehensive
Breast Program
Orlando Health Cancer Institute
Professor of Surgery
University of Central Florida
Orlando, FL



Jennifer L. Marti, MD

Assistant Professor, Surgery
Breast Surgical Oncology
Mount Sinai-Icahn School of
Medicine
New York, NY



**Beryl McCormick, MD,
FACP**

Attending Radiation Oncologist
Department of Radiation
Oncology
Memorial Hospital
Professor of Radiology
Weill Cornell Medical School
New York, NY




Babak Mehrara, MD

Chief of Plastic and
Reconstructive Surgery
Memorial Sloan Kettering Cancer
Center
New York, NY

FACULTY



Elizabeth Morris, MD
Professor and Chair of Radiology
UC Davis Health
Sacramento, CA



Hyman B. Muss, MD
Mary Jones Hudson
Distinguished Professor of
Geriatric Oncology
Professor of Medicine University
of North Carolina
Director of Geriatric Oncology
Lineberger Comprehensive
Cancer Center
Chapel Hill, NC



William Newman
Litigation Attorney & Partner
Oberheiden, P.C.
New York, NY



Anne O'Dea, MD
Associate Professor Breast
Medical Oncology
Director, Breast Cancer
Survivorship
University of Kansas School of
Medicine
Kansas City, KS



Joyce O'Shaughnessy, MD
Celebrating Women Chair in
Breast Cancer Research
Chair, Breast Cancer Research
Program
Baylor University Medical Center
Chair, Breast Cancer Research
Texas Oncology/US Oncology
Network
Dallas, TX



Edith A. Perez, MD
Chief Medical Officer
Bolt Biotherapeutics, Inc.
Professor of Medicine
Mayo Clinic
Redwood, CA



Mark E. Robson, MD
Chief, Breast Medicine Service
Memorial Sloan Kettering Cancer
Center
Professor of Medicine
Weil Cornell Medicine College
New York, NY



George W. Sledge, Jr. MD
Executive Vice President
Chief Medical Officer
Caris Life Sciences
Palo Alto, CA

FACULTY



Tiffany A. Traina, MD

Vice Chair, Oncology Care
Section Head, Triple Negative
Breast Cancer Clinical Research
Program
Associate Attending Physician
Breast Medicine Service
Memorial Sloan Kettering Cancer
Center
Associate Professor
Weill Cornell Medical College
New York, NY



Jessica A. Wilcox, MD

Assistant Attending Physician
Memorial Sloan Kettering Cancer
Center

BIOGRAPHIES



Maria Theodoulou, MD (Course Chair & Moderator) is recognized nationally and internationally for her breast cancer clinical research. Before joining New York Oncology Hematology, Dr. Theodoulou was an attending physician at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at the Joan and Sanford Weill Medical College of Cornell University, both in New York City. Dr. Theodoulou is board certified in internal medicine as well as medical oncology.

Dr. Theodoulou's passion for clinical research is patient-driven, constantly searching for individualized therapy with minimal toxicities. She is a recipient of multiple prestigious awards, including Leading Physicians of the World Top Breast Medical Oncologist in New York City 2019 and 2020, the Hally Yacino Steiner Award- Susan G. Komen for the Cure Greater New York City, Lifetime Achievement Award Cyprus Federation of America, Irka Wozniak Memorial Lecture Award Sass Foundation for Medical Research, Commendation Office of Comptroller City of New York, Outstanding Physician Award Sass Foundation for Medical Research, Hellenic Medical Society Kalopothakes Distinguished Female Physician Award, ASCO Merit Award. In 2022 Dr. Theodoulou was awarded the Presidential Medal from the Republic of Cyprus for her work in Breast Cancer.

Dr. Theodoulou is presently the Program Director of Breast Cancer Medicine at New York Oncology Hematology, the organizer and host/moderator of the NYOH Breast Cancer Symposium 2019, 2020, 2021, 2022, and 2023 a nationally and internationally recognized CME educational program, as well as the host of the Fireside Virtual Chat Panel and Live Breast Cancer Survivorship Education for Patients, their family and friends.



Francis P. Arena, MD, FACP is the director of one of New York's largest oncology practice groups, The NYU Langone Arena Oncology Center, in Lake Success, NY. He is also a Clinical Associate Professor of Medicine at New York University and Adjunct Clinical Assistant Professor of Medicine at Cornell University Medical College.

Dr. Arena received his Bachelor of Science Degree from Fordham University and his Medical Degree from Cornell University Medical College. His internship and residency were carried out at New York Hospital/Memorial Hospital, after which Dr. Arena served as Chief Medical Resident and later as Hematology/Oncology Fellow at the Memorial Sloan-Kettering Cancer Center. He is Board Certified in Internal Medicine and in Medical Oncology.

Because of his keen interest in cancer research and preventative cancer care, Dr. Arena helped establish and is the president of the SASS Foundation for Medical Research, which supports medical fellows at a number of hospitals. He is on the Advisory Board of "1 in 9", the Breast Cancer Coalition, and serves as a consultant for numerous pharmaceutical companies. Dr. Arena is widely published and has lectured extensively in his field. He is an Assistant Editor of the journal Oncology and previously

on the Editorial Board of the Community Oncology journal. Dr. Arena has been the recipient of multiple awards and citations for his work in oncology and breast cancer. Some of these awards include the David award given by Networking magazine, The Eileen Dryer Award by the Sass Foundation, the Il Leone de San Marco award in medicine by the Italian -American league of Westchester and the Bronx and has been cited in repeated years as one of the top oncologists in the New York Metropolitan area by the Castle Connelly magazines and Newsday. Frank lives with his wife and wonderful children in Long Island, NY.


Dr. Arena was the co-producer of the Bermuda Pink Conference Cancer On Breast Cancer and was solely responsible for assembling the expert panel of doctors from NYU Langone, Weill Cornell, Sloan Kettering, North Shore LIJ and Harvard Medical. He received the prestigious Bermuda International Citizenship Award for his moderating and production of the conference.



Jeanne Carter, PhD currently serves as the Head of the Female Sexual Medicine and Women's Health Program, Gynecology Service, Department of Surgery. This program provides individual interventions to female cancer patients, women at risk of cancer, and survivors coping with the physical and emotional challenges of cancer treatment. She has a dual appointment in the Department of Surgery, Gynecology Service and Department of Psychiatry as an Attending Psychologist. She had an active role in the cooperative group setting of the Gynecologic Oncology Group (GOG), participating as a member of the GOG Quality of Life and Health Outcomes Research Committee (2004-2013), Cancer Prevention and Control (CPC) Committee (2010-2014), and with the merger of the cooperative groups currently serves on the NRG Oncology Group's Patient-Centered Outcomes Research (PCOR) committee and NRG Cancer Prevention and Control (CPC) Committee.

Some of her research includes serving as the Quality-of-Life Study Chair on NRG-CC0008 (A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]) and GOG-0278 (Non-Radical Surgical Therapy for Stage IA1-IB1 (≤ 2 cm) Cervical Cancer; PI Study Chair, Allen Covens). In addition she served as QOL Study Chair for GOG-244, a clinical trial prospectively investigating the incidence and quality-of-life impact of lower extremity lymphedema in women undergoing radical surgery for gynecologic malignancy, was the recipient of a grant from the Lance Armstrong Foundation to examine the psychosexual impact of impaired fertility in female cancer survivors (Carter J, et al. J Cancer Survivorship 2010 Sep;4(3):236-46.) and the PI on a clinical trial investigating a non-hormonal vaginal moisturizer in postmenopausal cancer survivors experiencing estrogen deprivation symptoms".

Her academic career has focused on cancer, symptom management and treatment effects, PROs (patient reported outcomes), QOL and survivorship as a lecturer, author, clinician and researcher on multiple protocols both as PI and Co-PI.



Chau T. Dang, MD has an interest in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer. Dr. Dang focuses on developing more effective and less toxic treatment strategies for women with this disease. Her research and an investigator-initiated trial at Memorial Sloan Kettering has led to the widespread use and National Comprehensive Cancer Network (NCCN) endorsement of a dose-dense, anthracycline/taxane-containing chemotherapy regimen followed by trastuzumab in patients with early stage HER2-positive breast cancer. A second investigator-initiated study that evaluated dual anti-HER therapy with trastuzumab and pertuzumab and chemotherapy for patients with HER2-positive metastatic breast cancer led to the NCCN endorsement of this regimen as a standard option in treating patients with metastatic HER2-positive breast cancer. A third investigator-initiated study on dual anti-HER2 therapy with trastuzumab and lapatinib with chemotherapy also had an impact on research worldwide. Dr. Dang and her colleagues are currently leading other research trials, both locally and internationally that focus on the unique cardiac toxicities of anthracyclines and anti-HER2 agents. To allow for improved patient selection and monitoring, she studies cardiac biomarkers, with a future goal of facilitating early interventions to minimize acute and late cardiac effects of cancer treatment.

Dr. Dang is board-certified in internal medicine and medical oncology with clinical expertise in breast cancer. She received her MD at the Medical University of South Carolina followed by Internal Medicine Residencies at Allegheny General Hospital/Medical College of Pennsylvania and Fellowships in Hematology/Oncology at Memorial Sloan Kettering Cancer Center.



VK Gadi, MD, PhD is a physician scientist and medical oncologist. He completed the Medical Scientist Training Program at the U of Alabama at Birmingham with PhD and MD degrees earned in 1999 and 2000, respectively. Following 20 years in Seattle coming up through the medicine and oncology training, and faculty ranks at the U of Washington and Fred Hutch Cancer Center, Dr. Gadi relocated to the U of Illinois Chicago in 2020 to tackle new leadership opportunities currently serving as the Deputy Director of the Cancer Center. He is both a breast cancer clinician and a laboratory-based investigator. His continuously funded laboratory research made foundational contributions in the fields of immunology, cancer biology, diagnostics and therapeutics.



Heidi E. Godoy, D.O. joined New York Oncology Hematology (NYOH) on December 1, 2021, expanding our service line offerings at our Albany Cancer Center to include gynecologic oncology and surgery. Dr. Godoy specializes in medically and surgically treating cancers of female reproductive organs, including ovarian, endometrial, and cervical cancers.

“Dr. Godoy joining our practice allows us to increase access to care to our patients and the Capital Region community. Her surgical experience and specialization in this area of oncology will give us additional insight into the latest treatments, technologies, therapies, and precision medicine for our female patients with gynecologic cancers. We look forward to growing and expanding this service line under her leadership,” said Todd Doyle, MD, NYOH radiation oncologist and practice president.

NYOH anticipates expanding gynecologic oncology and surgery to our Hudson Cancer Center in early 2022.

Dr. Godoy is board-certified in obstetrics and gynecology, gynecology oncology and robotics. She completed her fellowship at Roswell Park Cancer Institute in gynecologic oncology. Prior to NYOH, she spent the past nine years at Women’s Cancer Care Associates as a gynecologic oncologist and surgeon. She is a member of several professional associations, including the American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncologists.



Yasmin Hasan, MD Associate Professor of Radiation Oncology, specializes in the treatment of breast and gynecologic cancers. She uses highly targeted, localized radiation techniques -- such as brachytherapy and intensity-modulated radiotherapy (IMRT) -- to minimize damage to the healthy tissue surrounding a malignancy.


Dr. Hasan’s research focuses on finding patterns in breast cancer and gynecologic cancer outcomes, with the goal of developing preventative therapies and improving definitive treatment.

An accomplished author, Dr. Hasan has published several articles in peer-reviewed journals and contributed to book chapters on the role of external beam radiation in the management of malignant diseases.



Claudine Isaacs, MDCM, FRCPC is a Professor of Medicine and Oncology, Associate Director for Clinical Research and Leader of the Clinical Breast Cancer Program at the Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University. She is also the Medical Director of the Fisher Center for Hereditary Cancer and Clinical Genomics Research. She has extensive experience in the conduct of clinical trials focusing on early stage and metastatic breast cancer and currently serves as Co-Chair Endocrine Resistance Working Group of the Translational Breast Cancer Research Consortium (TBCRC) and as Chair of the Clinical Trials Operations Working Group for the I-SPY 2 Trial. She has authored over 250 peer-reviewed publications and edited two textbooks, including one on hereditary breast cancer. She has served on a number of national committees including the Scientific Program

Committees at ASCO, the ASCO Breast Cancer Guideline Advisory Group, the Breast Oncology Local Diseases Task Force of the Breast Steering Committee of the NCI.



Neil Mukund Iyengar, MD is a board-certified Medical Oncologist and clinical-translational researcher at Memorial Sloan Kettering Cancer Center (MSKCC) where he specializes in the care of patients with breast cancer. He also holds joint research appointments at the Rockefeller University Center for Clinical and Translational Science and Weill Cornell Medicine in New York.

Dr. Iyengar received his undergraduate and medical degrees from the University of Illinois at Chicago accelerated degree program where he graduated with the College's highest honors (University Scholar). He completed residency training in Internal Medicine at the University of Chicago Medical Center followed by a fellowship in medical oncology and hematology at MSKCC. He now holds a faculty position as an Associate Attending on the Breast Medicine Service at MSKCC. Dr. Iyengar's research program investigates interventions to improve metabolic health as a strategy to reduce breast cancer risk and mortality. His group is testing the anti-cancer effects of structured exercise and nutritional interventions in people at high risk or diagnosed with breast cancer. Dr. Iyengar's research is also investigating the use of drugs that treat metabolic disorders, such as diabetes and obesity, to improve the effectiveness of cancer therapies.

In an effort to rapidly translate this work, Dr. Iyengar also leads the Healthy Living Program, a novel cancer care model that aims to translate research findings from lifestyle intervention trials into clinical practice during and after cancer therapy. His work has been recognized and awarded by several organizations, including research grants from the National Cancer Institute, American Cancer Society, the Breast Cancer Research Foundation, Conquer Cancer the ASCO Foundation, and others. He has published numerous original research articles and has been an invited speaker at several international conferences.



Komal Jhaveri, MD, FACP is an Associate Attending Physician and serves as the Section Head for the Endocrine Therapy Research Program within the Breast Medicine Service and as the Clinical Director for the Early Drug Development Service at MSKCC. She is an Associate Professor in the Department of Medicine (DOM) at Weill Cornell Medicine in New York. She earned her medical degree followed by a training in nuclear medicine from the University of Mumbai. She later completed her Internal Medicine residency from Icahn School of Medicine at Mount Sinai (Morningside/West) Program in New York and her Medical Oncology/ Hematology fellowship at MSKCC. From July 2012-May 2015, she served as an Assistant Professor in the DOM at New York University and as an Attending Physician at the Langone Medical Center and at Bellevue Hospital.

Dr. Jhaveri's research interests focus on the development of improved therapies for patients with breast cancer, by conducting novel clinical trials integrated with translational biomarker work through acquired biospecimen (cfDNA and tumor) or imaging analyses. She has led the development of PI3K/Akt inhibitors, FGFR inhibitors, ERBB2 inhibitors, oral SERD's, Antibody-drug conjugates, amongst others.

Dr. Jhaveri serves as a member of the ASCO/TAPUR Molecular Tumor Board. She is the Co-Chair for the Endocrine Resistance working group within the Translational Breast Cancer Research Consortium. Her work has been presented at annual scientific meetings of ASCO, AACR, ESMO, SABCS and has been published widely in many reputable journals.



Quincy LaPlant, MD, PhD is a graduate of Mount Sinai School of Medicine, with a PhD in Neuroscience from UT Southwestern, and completed radiation oncology residency at Memorial Sloan Kettering Cancer Center, where he is an Assistant Attending in Radiation Oncology with clinical expertise in breast cancer with practice located at MSKCC Westchester. Dr. LaPlant has a basic translational research program in the biomedical engineering cancer nanomedicine laboratory of Dr. Daniel Heller at MSKCC, with focus on the development of radiation-guided nanomedicines for breast cancer and brain metastases.



Eleftherios (Terry) P. Memounas, MD, MPH, FACS is Medical Director of the Comprehensive Breast Program at Orlando Health Cancer Institute, Professor of Surgery at University of Central Florida and Clinical Professor of Clinical Sciences, Florida State University College of Medicine. He is Chair of the NRG Oncology Breast Committee and past Chair of the NSABP Breast Committee.

He received his medical degree from the University in Athens in Greece, and a Master of Public Health (Epidemiology) from the University of Pittsburgh. Following his general surgery residency, he completed an oncology research fellowship at the University of Pittsburgh and a surgical oncology fellowship at Roswell Park Cancer Institute in Buffalo, New York.

He has authored or co-authored over 450 abstracts, manuscripts, and book chapters, and he has given numerous presentations on breast cancer at various regional, national, and international symposia. His clinical research has focused on the surgical and adjuvant treatment of early-stage breast cancer.



Jennifer L. Marti, MD is a surgeon specializing in breast surgical oncology. Her practice focuses on the treatment of benign and malignant disorders of the breast. She has expertise in all aspects of breast surgery, including newer techniques such as hidden scar lumpectomy, nipple sparing mastectomy and targeted and targeted axillary lymph node dissection.

Dr. Marti offers a personalized approach to treatment and engages in shared decision-making with all patients, carefully balancing the harms and benefits of all proposed interventions. She offers carefully selected patients the option of active surveillance for “high risk” lesions of the breast, and soon for DCIS as part of a clinical trial, which can help avoid unnecessary surgery.



Beryl McCormick, MD, FACP has specialized in the treatment of Breast Cancer with radiation since completing her residency at Memorial Sloan Kettering Cancer Center. In the course of her career, she was a founding member of the NCCN Breast Guidelines Committee, serving with that group for over 20 years, the Chair for 10 years of the RTOG Breast Committee, and the Acting Chairman of the Department of Radiation Oncology for over 3 years, until the present chair was named. Her main research contributions have been thru her work in cooperative groups, namely RTOG and NRG. She ensured that the CALGB 9343 “Elderly Trial” reached accrual with her RTOG committee’s strong support, demonstrating that older women with Stage I breast cancer had minimal benefit from radiation and initiated the first cooperative group trials of Partial Breast Irradiation (PBI). Once those initial feasibility trials were published, she worked closely with the NCI and NSABP group in her role as chair of the RTOG Breast Committee, to launch the large prospective trial comparing whole breast radiation to PBI, the B-39 trial. She is also the PI of the RTOG DCIS Trial for “good Risk” breast cancer patients, also showing that breast radiation could safely be omitted in many patients who presented with so-called “good risk” DCIS. She is a dedicated teacher for medical students and residents, a mentor for junior faculty, and has made numerous “Best Doctor” lists throughout her career.



Babak J. Mehrara, MD is the Chief of the Plastic and Reconstructive Surgery Service and the Peter G. Cordeiro Endowed Chair in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK), with a joint appointment as Professor of Surgery at Weill Cornell Medical College. Dr. Mehrara is an oncologic reconstructive surgeon with a broad background in both the clinical management and the biology of cancer. He has authored more than 250 peer-reviewed publications and serves as the Director of the National Institutes of Health-funded Lymphatic Biology Laboratory at MSK.



Elizabeth Morris, MD is Professor and Chair of Radiology at the University of California, Davis (UCD) School of Medicine. Dr. Morris graduated summa cum laude from UCD in Biochemistry and received her medical degree from the University of California, San Francisco (UCSF). She completed her residency at Weill Cornell Medical College (WSKCC) where she remained on faculty until December 2020 where she was the Chief of the Breast Imaging Service and Larry Norton Endowed Chair.

Dr. Morris is a fellow of the American College of Radiology (ACR), Society of Breast Imaging (SBI) and International Society of MR in Medicine (ISMRM) and is past president of the SBI. She is the inaugural Equity Diversity & Inclusion officer of the ISMRM and co-chair of the Women of ISMRM (WISMRM).

Her research focus is on how best to use newer techniques such as MRI for early breast cancer detection and to improve the workup of breast lesions. In collaboration with her colleagues, she has written over 230 papers, 40 chapters, and 5 books about breast disease with an emphasis on the use of MRI. She has lectured widely both nationally and internationally at over 320 conferences. She has mentored over 50 international research fellows. She has grants from NCI, RSNA, Komen Foundation, and Breast Cancer Research Foundation. She has authored a book "Breast MRI: Diagnosis & Intervention". Her recent research efforts have involved looking at imaging biomarkers to assess risk and treatment response.



Hyman B. Muss MD is an experienced clinician-scientist, the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina School of Medicine, and the Director of the Geriatric Oncology Program at the UNC Lineberger Comprehensive Cancer Center Program. His interest is education and research focused on cancer in older patients and is an internationally recognized leader in this area. His particular interest and research expertise is in the care of breast cancer patients with a focus on the management of older women. He also has a major interest in breast cancer survivorship and long-term toxicity of treatment. After working with his previous UNC colleague, Dr. Ned Sharpless, he is exploring the role of biomarkers of aging and their potential role as predictors of toxicity and survival.

Dr. Muss has developed and been PI of multiple clinical and translational trials including lead author of an NCI-sponsored intergroup trial that compared standard care with oral chemotherapy in older women with early-stage breast cancer and which for the first time showed the value of chemotherapy in this older populations. He serves as the mentor for medical students, medicine residents, junior faculty, and more recently Geriatric Oncology fellows. He previously co-chaired the Alliance Committee on Cancer in Older Adults. He has been co-chair of the Breast Committee for the CALGB, Chair and a member of the board of Directors of the American Board of Internal Medicine, and a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and the ASCO Foundation. He was awarded the B.J. Kennedy Award in Geriatric Oncology by ASCO, the Susan G. Komen for the Cure Brinker Award for Scientific Distinction in Clinical Research, and an honorary Doctor of Science Degree from his alma mater, Lafayette College. He has served in the U.S. Army in Vietnam where he was awarded the Bronze Star medal.



Will Newman is an attorney who represents clients in commercial lawsuits, employment disputes, and white collar criminal cases. He began his career as a transactional attorney at White & Case LLP in 2008, and is currently a partner at Oberheiden, P.C. The Wall Street Journal and the New York Post have cited Will as an authority on legal issues. He is an associate editor of the American Bar Association magazine, Litigation News, and the author of the litigation blog, Unpredictable.

Before his work as a lawyer, Will studied at Brown University, the New York University School of Law, and the University of Copenhagen. He also taught technology classes to elementary school students at the Village Community School in Manhattan.



Dr. Anne O'Dea is an Associate Professor at the University of Kansas Medical Center where she also serves as the Medical Director for both Breast Cancer Survivorship and Breast Cancer Clinical Research Program Services. Her primary focus in clinical practice is on the treatment of breast malignancy as well as breast cancer risk assessment, prevention and survivorship. Her clinical practice spans across the state of Kansas and across the region serving women with breast cancer from urban and rural communities. She has dedicated her career to promoting breast screening, genetic counselling and preventive measures such as healthy diet, weight management and exercise. Dr. O'Dea's research interests span across the cancer control continuum and in 2016 she was responsible for the largest number of women with breast cancer enrolled into breast cancer treatment and supportive care trials. She serves as a co-investigator for several treatment and survivorship trials, including those focused on triple negative breast cancer, advanced breast cancer, and survivorship issues including lifestyle modification and cognitive impairment.



Joyce A O'Shaughnessy, MD is the Celebrating Women Chair in Breast Cancer Research at Baylor University Medical Center, and Chair of Breast Cancer Research for the US Oncology Network in Dallas, TX. She earned her medical degree from Yale University School of Medicine, and completed her residency in Internal Medicine at Massachusetts General Hospital, and fellowship in Medical Oncology from the National Cancer Institute. Dr O'Shaughnessy specializes in medical oncology and focuses her practice and clinical research on breast cancer treatment. She has authored or co-authored more than 250 peer-reviewed articles that have been published in journals such as Breast Cancer Research and Treatment, Clinical Breast Cancer, Journal of Clinical Oncology, and Annals of Oncology. Dr O'Shaughnessy serves as Diplomate of the American Board of Internal Medicine and National Board of Medical Examiners. She is a member of the American Association for Cancer Research, American Society of Clinical Oncology, American Medical Women's Association, and Texas Medical Association.



Edith A. Perez, MD, Chief Medical Officer is an internationally recognized translational researcher and cancer specialist known for her strategic vision in innovative and patient-centric clinical trial design. Dr. Perez joined Bolt in 2020 and has set direction for the organization's clinical strategy and development and oversees regulatory affairs, pharmacovigilance, biostatistics, and medical affairs for the company's diverse clinical development and early-stage immuno-oncology pipeline.

In addition to her work at Bolt Biotherapeutics, Dr. Perez is chair of the Health Equity Committee and a member of the Scientific Advisory Committee for Stand Up to Cancer, a member of the Puerto Rico Science, Technology & Research Trust and has been involved in diversity leadership and philanthropic initiatives with the American Society of Clinical Oncology, the American Association for Cancer Research and The DONNA Foundation. She also serves on the editorial boards of multiple academic journals and is a member of the Board of Directors and the Clinical Advisory Board for Artiva Biotherapeutics. Dr. Perez was formerly professor of medicine at Mayo Clinic, where she practiced for over two decades. Prior to joining Bolt, Dr. Perez was vice president and head of the BioOncology-U.S. Medical Affairs unit at Genentech, a member of the Roche Group, where she oversaw all U.S. hematology and oncology medical affairs. In that role, Dr. Perez led hundreds of trials and was involved in the launch of six drugs, including Gazyva (obinutuzumab) for patients with lymphoma, Perjeta (pertuzumab) for patients with early-stage HER2+ breast cancer, Alesensa (alectinib) for patients with lung cancer and Tecentriq (atezolizumab) for bladder cancer and non-small cell lung cancer patients.

Dr. Perez earned her medical degree from the University of Puerto Rico School of Medicine in San Juan and completed her residency in internal medicine at the Loma Linda University Medical Center in California. In addition, Dr. Perez completed her fellowship training at the University of California, Davis. She also completed the Executive Development Program at the Harvard Kennedy School and the Executive Leadership and the Management Executive Programs at the Wharton School of the University of Pennsylvania. Dr. Perez is board certified in internal medicine, medical oncology, and hematology.



Mark E. Robson, MD graduated from the University of Virginia School of Medicine in Charlottesville, Virginia, and did his internal medicine residency and hematology-oncology fellowship training at Walter Reed Army Medical Center in Washington DC. He is currently Chief of the Breast Medicine Service in the Department of Medicine at Memorial Hospital in New York, Attending Physician on the Breast Medicine and Clinical Genetics Services, and a Member of the Memorial Sloan Kettering Cancer Center. He is also a Professor of Medicine at Weill Cornell Medical College. His clinical research has concentrated on the optimal application of germline information to the management of cancer patients, particularly those with breast cancer. He has been a lead investigator for a number of trials of PARP inhibitors in patients with BRCA mutation – associated breast cancer. In addition to studying PARP inhibition as a therapeutic strategy, he has worked on developing newer models for the acquisition of germline information, including “mainstreaming” through test ordering by primary oncology providers and broad genomic screening in the context of somatic mutational profiling. He has led the writing of several ASCO statements on genetic and genomic testing and has also participated in the development of ESMO opinions on the same topics. He is an associate editor for the Journal of the National Cancer Institute. He is also a Fellow of the American Society of Clinical Oncology, past Chair of the Ethics Committee of that organization and has served several terms on the ASCO Cancer Prevention Committee and its Cancer Genetics subcommittee.



George W. Sledge, Jr., MD is the Executive Vice President, Chief Medical Officer at Caris Life Sciences. He is also an Adjunct Clinical Professor of Medicine at the Stanford University School of Medicine where he serves as a member of the Division of Oncology. Our basis current platform involves performing whole exome and whole transcriptome sequencing on essentially all solid tumors, using Illumina state-of-the-art NovaSeq machines; we have more of these machines than any other institution on the planet. We at Caris Life Sciences are in the process of launching a liquid assay, called Caris Assure, which, like our solid tissue assay, involves whole exome and whole transcriptome sequencing, in addition to germline mutation profiling and CHIP subtraction off the buffy coat. Dr. Sledge is Past President of the American Society of Clinical Oncology, and currently serves as the Chief Scientific Advisor for the Susan G. Komen Foundation and as a member of the scientific advisory board for the Triple Negative Breast Cancer Foundation.



Tiffany A. Traina MD is an Associate Attending Physician on the Breast Medicine Service at Memorial Sloan Kettering Cancer Center. She serves as the Vice Chair, Oncology Care for the Department of Medicine and Section Head of the Triple Negative Breast Cancer Clinical Research Program. She is Co-Chair of the MSK Outpatient Operations Committee and has served as the Clinical Director of the Breast Medicine Service. She is Associate Professor of Medicine at Weill Cornell Medicine in New York City. Her research program centers on the development of therapies for patients with breast cancer, with a particular focus on Triple Negative Breast Cancer and the role of the androgen receptor. Dr. Traina has served on numerous ASCO committees including the Scientific Program Committee for the ASCO Triple Negative Breast Cancer/Cytotoxics/Local Therapy track and she is past Chair for the ASCO Membership Committee 2020-2021 as well as the Co-Chair of the Breast Cancer Guidelines Advisory Group. Dr Traina is a graduate of the 2016-2017 ASCO Leadership Development Program and the MSK Physician Executive Development Program. She is a founding member of the Translational Breast Cancer Research Consortium Triple Negative Breast Cancer Working Group. Her research efforts have led to many publications, peer-reviewed funding, and competitive funding. She has received recognition for her teaching from Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine and has been acknowledged with the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation and the Hero Award from the Triple Negative Breast Cancer Foundation.



Jessica A Wilcox, MD is an Assistant Attending Neuro-Oncologist at Memorial Sloan Kettering Cancer Center and she specializes in the treatment of central nervous system metastases. Her research involves the development of early phase clinical trials and novel therapeutic targets for patients with leptomeningeal metastases, and multimodality screening for asymptomatic CNS metastasis in HER2+ breast cancer.

PRODUCT THEATER


Non-CME Ancillary Events - Located in WEST ROOM / VAULT

FRIDAY, AUGUST 4th, 2023 – 7:50AM

Clinical Case Reviews: Treatment of a Broad Range of Patients With HR+/HER2- Metastatic Breast Cancer

PROVIDED BY:

Pfizer, Inc.



GUEST SPEAKER:

Neil Iyengar, MD

Associate Attending
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medicine Associate
Attending Rockefeller University
New York, NY

FRIDAY, August 4th, 2023 – 11:45AM

Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings. PP-AL-US-2989 © Lilly USA, LLC 2021. All rights reserved.

Join this peer-led program to explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings.

PROVIDED BY:

Eli Lilly and Company



GUEST SPEAKER:

Peter A. Kaufman, MD

Professor of Medicine,
Hematology/Oncology Division
Department of Medicine Cancer
Center Member
University of Vermont Medical
Center
Burlington, VT

FRIDAY, August 6th 2023 – 5:30PM

Expanded Horizons: A Post-endocrine Option for Patients with HR+/HER2- mBC

Addressing the Needs of Patients Across the HR+/HER2- Landscape

PROVIDED BY:

Novartis Oncology



GUEST SPEAKER:

Patrick Kugel MBA

Associate Director of Breast
Cancer Peer to Peer Marketing
Novartis

SATURDAY, August 5th, 2023 – 7:50am

Brain Metastases in HER2+ Metastatic Breast Cancer: Current Clinical Insights

PROVIDED BY:

Seagen, Inc.



GUEST SPEAKER:

Joyce O'Shaughnessy, MD

Medical Director, US Oncology
Research Director, Breast
Cancer Research, US Oncology
Co-Chair of Breast Cancer
Research and Chair of Breast
Cancer Prevention Research
at Baylor-Sammons Cancer
Center and for The US Oncology
Network; Member of the
Scientific Advisory Board for US
Oncology Research Network.
Dallas, TX

SATURDAY, August 5th, 2023 - 12:05PM

Expanded Horizons: A Post-endocrine Option for Patients with HR+/HER2- mBC

Gilead Sciences, Inc., is proud to present a live meeting on HR+/HER2- metastatic breast cancer.

PROVIDED BY:

Gilead Sciences, Inc.



GUEST SPEAKER:

Anne O'Dea, MD

Medical Director, Breast Cancer
Survivorship Center; Assistant
Professor of Oncology
Affiliations:
Medical Director
University of Kansas School of
Medicine
Kansas City, Kansas

SATURDAY, August 5th, 2023 - 4:10PM

Once-daily oral ORSERDU (elacestrant)

Educational presentation detailing the once-daily oral ORSERDU (elacestrant) medication.

PROVIDED BY:

Stemline Therapeutics



GUEST SPEAKER:

Vijayakrishna Gadi, MD, PhD

Medical Oncologist Professor and
Director of Medical Oncology
Department of Medicine
Associate Director, Translational
Oncology
Affiliations:
University of Illinois in Chicago
Medical Center, Winnetka, IL.

SUNDAY, August 6th, 2023 – 11:40AM

***An Overview of Clinical Data for ENHERTU
(fam-trastuzumab deruxtecan-nxki) in
HER2-Expressing Metastatic Breast Cancer***

Please join us for an informative, expert-led discussion presented by Daiichi Sankyo, Inc. and AstraZeneca to explore the data on the efficacy and safety of ENHERTU.

PROVIDED BY:

Daiichi Sankyo Inc. and AstraZeneca



GUEST SPEAKER:

Francis Arena, MD

Affiliations:

NYU Langone Arena Oncology

**WIN AN
iPAD PRO:**



**You will receive raffle ticket(s) at the end
of each Product Theater you attend.**

2 Raffle Tickets for **every early morning session** you attend.

1 Raffle Ticket for **every midday session** you attend.

2 Raffle Tickets for the **early evening sessions** you attend.

iPad Pro Specifications:

Personalized 11-inch iPad Pro Wi-Fi 1TB - Space Gray, AppleCare+, Apple Pencil,
Magic Keyboard for iPad Pro 11-inch - Black - Estimated value: \$2,000

5th Annual BREAST CANCER SYMPOSIUM

Disparities on a Cellular Level & Patient Level

is supported by grants provided by:

Gilead Sciences, Inc. • Puma Biotechnology, Inc. • Seagen, Inc.

Thank you to our Sponsors and Exhibitors:

PRODUCT THEATER

Daiichi Sankyo, Inc.
and AstraZeneca
Gilead Sciences, Inc.

Eli Lilly and Company
Novartis Oncology
Pfizer, Inc

Seagen, Inc.
Stemline Therapeutics

PLATINUM SPONSORSHIP

Gilead Sciences, Inc

GOLD SPONSORSHIP

Pfizer, Inc.

Puma Biotechnology

SILVER SPONSORSHIP

Novartis Oncology

BRONZE SPONSORSHIP

Agendia, Inc
AstraZeneca
BeiGene
Breast Cancer Index,
BioTheranostics, Inc.
Caris Life Sciences

Daiichi Sankyo, Inc.
Foundation Medicine
Genentech, Inc.
Incyte Corporation
Eli Lilly and Company
Merck & Co, Inc

Mirati Therapeutics
Novartis Oncology
Sanofi
Seagen, Inc.
Stemline Therapeutics

NOTES

[illegible]

NOTES

[illegible]